Global reach RoukenBio serves customers in over 27 countries and is expanding its discovery center in Motherwell, Scotland, with recent UK and Northern Europe facility expansion openings. Sales opportunity: position RoukenBio as a scalable CRO partner for multinational biotech portfolios and early discovery programs seeking regionalized support and expanded geographic coverage.

Integrated services Offers end-to-end in vitro drug discovery services including immunology, bioanalytical, cell line engineering, molecular biology, bioassay development, and safety and efficacy assessments, along with GMP-ready potency assays. Sales angle: bundle multiple services for integrated project workflows to reduce vendor fragmentation and accelerate timelines for therapeutic modalities.

Advanced platforms Features unique capabilities such as the customizable inducible cell line platform IndEx-2 and disease-pathology-replicating assay solutions to model complex states. Opportunity: pitch as a collaborator for high-fidelity, translational assays and bespoke cell models for novel modalities like cell therapies, antibodies, and degraders.

Strategic focus areas Concentrates on inflammation, auto-immunity, immuno-oncology, and oncology, with work across antibodies, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines, and ADCs. Sales angle: align with clients in these therapeutic areas to offer specialized assays, IND-enabling data generation, and GMP-ready testing to de-risk early development.

Growth potential Revenue range indicates a growing, mid-sized CRO with international footprint and expanding capabilities, supported by a collaborative, partner-focused model. Business development takeaway: target mid-stage biotech and biopharma companies seeking agile, personalized CRO partnerships to accelerate discovery programs and satisfy IND-time commitments.